Optimal Timing of Hepatitis B Vaccination After Transplants

Launched by INSTITUTE OF HEMATOLOGY & BLOOD DISEASES HOSPITAL, CHINA · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is focused on finding the best time to give a hepatitis B vaccination to patients who have undergone a specific type of transplant called hematopoietic cell transplantation (HCT). Researchers want to see if giving the vaccine 3 months or 6 months after the transplant works better for building immunity against hepatitis B. This study is important because it can help protect patients from a virus that can cause serious liver problems.

To be eligible for this trial, participants must be at least 16 years old and have received an HCT. They also need to be in a state called complete molecular remission, which means the cancer is not detectable in their body. Before joining, patients or their guardians will need to sign a consent form to show they understand the study. The trial is not yet recruiting, so patients will have to wait until it officially starts. Participants can expect to receive either of the vaccination schedules and will be monitored closely to see how well the vaccine helps their immune system.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients must be ≥ 16 years old;
• • 2. Patients receiving hematopoietic cell transplantation;
• • 3. Patients achieving complete molecular remission;
• • 4. Patients or their guardians have to sign an informed consent form before the start of the research procedure.
• Exclusion Criteria:
• • 1. Multiple transplantations;
• • 2. Donors' HBV-DNA or HBsAg are positive;
• • 3. Patients' HBV-DNA or HBsAg are positive before transplantation or \< 3 months after transplantation;
• • 4. Patients who are unable to comply with the research treatments and monitoring requirements due to mental or other medical conditions;
• • 5. Patients who are ineligible for the study due to other reasons which would cause unacceptable risks to the patients.